Summary
The RSV Partnering 2007-2013 report provides understanding and access to the RSV partnering deals and agreements entered into by the worlds leading healthcare companies.
The Influenza Partnering 2007-2013 provides understanding and access to the influenza partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an analysis of influenza partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors influenza technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of How payments are triggered – contract documents provide this insight where press releases do not.
This data driven report contains over 280 links to online copies of actual influenza deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of influenza partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in influenza partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.
Chapter 3 provides an overview of the leading influenza deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive directory of influenza partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of influenza technologies and products.
Report scope
Influenza Partnering 2007-2013 is intended to provide the reader with an in-depth understanding and access to influenza trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
Benefits
Influenza Partnering 2007-2013 provides the reader with the following key benefits:
The RSV Partnering 2007-2013 report provides understanding and access to the RSV partnering deals and agreements entered into by the worlds leading healthcare companies.
- Trends in RSV partnering deals
- Top RSV deals by value
- Deals listed by company A-Z, industry sector, stage of development, technology type
The Influenza Partnering 2007-2013 provides understanding and access to the influenza partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an analysis of influenza partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors influenza technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of How payments are triggered – contract documents provide this insight where press releases do not.
This data driven report contains over 280 links to online copies of actual influenza deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of influenza partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in influenza partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.
Chapter 3 provides an overview of the leading influenza deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive directory of influenza partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of influenza technologies and products.
Report scope
Influenza Partnering 2007-2013 is intended to provide the reader with an in-depth understanding and access to influenza trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
- Trends in influenza dealmaking in the biopharma industry since 2007
- Access to summary headline, upfront, milestone and royalty data
- The leading influenza deals by value since 2007
- Headline value
- Upfront payment value
- Royalty rate value
- Company A-Z
- Industry sector
- Stage of development at signing
- Deal component type
- Technology type
Benefits
Influenza Partnering 2007-2013 provides the reader with the following key benefits:
- In-depth understanding of influenza deal trends since 2007
- Access to summary headline, upfront, milestone and royalty data
- Comprehensive access to over 280 actual influenza deals entered into by the world’s biopharma companies since 2007
- Insight into key deal terms included in contracts, where disclosed
- Understand the key deal terms companies have agreed in deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
EXECUTIVE SUMMARY
CHAPTER 1 – INTRODUCTION
CHAPTER 2 – TRENDS IN INFLUENZA PARTNERING
2.1. Introduction
2.2. Influenza partnering over the years
2.3. Bigpharma influenza dealmaking activity
2.4. Influenza partnering by deal type
2.5. Influenza partnering industry sector
2.6. Influenza partnering by stage of development
2.7. Influenza partnering by technology type
2.8. Disclosed financial deal terms for influenza partnering
2.8.1 Influenza headline values
2.8.2 Influenza upfront payments
2.8.3 Influenza milestone payments
2.8.4 Influenza royalty rates
CHAPTER 3 – LEADING INFLUENZA DEALS
3.1. Introduction
3.2. Top Influenza deals by value
3.3. Top Influenza deals involving bigpharma
CHAPTER 4 – DEALMAKING DIRECTORY
4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
4.4. By industry sector
Academic
Bigpharma
Biotech
Drug delivery
Medical device
Diagnostic
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
4.5. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
4.6. By technology type
Analysis
Animal models
Assays
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Cell culture
Cell therapy
Clinical testing
Diagnostic - companion
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Imaging
Industrial chemicals
In vitro models
&nbs
CHAPTER 5 – PARTNERING RESOURCE CENTER
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
APPENDICES
Appendix 1 – Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports
TABLE OF FIGURES
Figure 1: Influenza partnering since 2007
Figure 2: Bigpharma – top 50 – influenza deals 2007 to 2011
Figure 3: Bigpharma influenza deal frequency – 2007 to 2011
Figure 4: Influenza partnering by deal type since 2007
Figure 5: Influenza partnering by industry sector since 2007
Figure 6: Influenza partnering by stage of development since 2007
Figure 7: Influenza partnering by technology type since 2007
Figure 8: Influenza deals with a headline value
Figure 9: Influenza deals with upfront payment values
Figure 10: Influenza deals with milestone payments
Figure 11: Influenza deals with royalty rates, %
Figure 12: Top influenza deals by value since 2007
Figure 13: Top influenza deals signed by bigpharma value since 2007
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions
CHAPTER 1 – INTRODUCTION
CHAPTER 2 – TRENDS IN INFLUENZA PARTNERING
2.1. Introduction
2.2. Influenza partnering over the years
2.3. Bigpharma influenza dealmaking activity
2.4. Influenza partnering by deal type
2.5. Influenza partnering industry sector
2.6. Influenza partnering by stage of development
2.7. Influenza partnering by technology type
2.8. Disclosed financial deal terms for influenza partnering
2.8.1 Influenza headline values
2.8.2 Influenza upfront payments
2.8.3 Influenza milestone payments
2.8.4 Influenza royalty rates
CHAPTER 3 – LEADING INFLUENZA DEALS
3.1. Introduction
3.2. Top Influenza deals by value
3.3. Top Influenza deals involving bigpharma
CHAPTER 4 – DEALMAKING DIRECTORY
4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
4.4. By industry sector
Academic
Bigpharma
Biotech
Drug delivery
Medical device
Diagnostic
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
4.5. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
4.6. By technology type
Analysis
Animal models
Assays
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Cell culture
Cell therapy
Clinical testing
Diagnostic - companion
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Imaging
Industrial chemicals
In vitro models
&nbs
CHAPTER 5 – PARTNERING RESOURCE CENTER
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
APPENDICES
Appendix 1 – Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports
TABLE OF FIGURES
Figure 1: Influenza partnering since 2007
Figure 2: Bigpharma – top 50 – influenza deals 2007 to 2011
Figure 3: Bigpharma influenza deal frequency – 2007 to 2011
Figure 4: Influenza partnering by deal type since 2007
Figure 5: Influenza partnering by industry sector since 2007
Figure 6: Influenza partnering by stage of development since 2007
Figure 7: Influenza partnering by technology type since 2007
Figure 8: Influenza deals with a headline value
Figure 9: Influenza deals with upfront payment values
Figure 10: Influenza deals with milestone payments
Figure 11: Influenza deals with royalty rates, %
Figure 12: Top influenza deals by value since 2007
Figure 13: Top influenza deals signed by bigpharma value since 2007
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions